Table 1.
Patient and disease characteristics of the entire cohort (n = 193)
| Variable | Results |
|---|---|
| Male/female | 83/110 |
| Age at diagnosis, median (IQR) | 32 (21–44) |
| Age at initiation TG, median (IQR) | 43 (33–56) |
| Hospital | |
| ▪ St. Thomas’ Hospital | 87 (45%) |
| ▪ East Surrey Hospital | 67 (35%) |
| ▪ Queen Elizabeth Hospital | 39 (20%) |
| Crohn’s disease (Montreal classification) | 123 (64%) |
| Age at diagnosis | |
| ▪ < 17 (A1) | 16 (19%) |
| ▪ 17–40 (A2) | 71 (58%) |
| ▪ > 40 (A3) | 29 (24%) |
| Location | |
| ▪ Ileal (L1) | 38 (31%) |
| ▪ Colonic (L2) | 15 (15%) |
| ▪ Ileocolonic (L3) | 62 (50%) |
| ▪ Upper gastrointestinal disease (L4) | 4 (3%) |
| Behaviour | |
| ▪ Nonstricturing, nonpenetrating (B1) | 45 (40%) |
| ▪ Stricturing (B2) | 36 (33%) |
| ▪ Penetrating (B3) | 26 (27%) |
| ▪ Perianal disease (p) | 23 (12%) |
| Ulcerative colitis (Montreal classification) | 64 (33%) |
| Extent | |
| ▪ Proctitis (E1) | 18 (30%) |
| ▪ Left-sided (E2) | 24 (37%) |
| ▪ Pancolitis (E3) | 21 (33%) |
| Severity | |
| ▪ Asymptomatic (S0) | 9 (14%) |
| ▪ Mild (S1) | 15 (24%) |
| ▪ Moderate (S2) | 18 (28%) |
| ▪ Severe (S3) | 22 (34%) |
| IBD unclassified | 6 (3%) |
| Drug failure prior to thioguanine initiation | 193 (100%) |
| ▪ Azathioprine | 123 (58%) |
| ▪ Mercaptopurine | 11 (5%) |
| ▪ Azathioprine and mercaptopurine | 59 (27%) |
| ▪ Azathiopurine and allopurinol | 76 (39%) |
| ▪ Anti-tumour necrosis factor | 77 (40%) |
| ▪ Methotrexate | 36 (19%) |
| ▪ Tacrolimus | 8 (4%) |
| Gastrointestinal surgery prior to thioguanine initiation | 63 (33%) |
| Follow-up in months, median (IQR) | 36 (22–53) |
| Treatment duration of thioguanine (months, IQR) | 23 (10–47) |